The significance of cancer stem cells (CSCs) in initiation and progression of colon cancer (CC) has been established. In this study, we investigated the utility of measuring mRNA expression levels of CSC markers EpCAM, LGR5 and LGR4 for predicting survival outcome in surgically treated CC patients. Expression levels were determined in 5 CC cell lines, 66 primary CC tumors and 382 regional lymph nodes of 121 CC patients. Prognostic relevance was determined using Kaplan-Meier survival and Cox regression analyses. CC patients with lymph nodes expressing high levels of EpCAM, LGR5 or LGR4 (higher than a clinical cutoff of 0.07, 0.06 and 2.558 mRNA copies/18S rRNA unit, respectively) had a decreased mean survival time of 32 months for EpCAM and 42 months for both LGR5 and LGR4 at a 12-year follow-up ( = 0.022, = 0.005 and = 0.011, respectively). Additional patients at risk for recurrence were detected when LGR5 was combined with the biomarkers CXCL17 or CEA plus CXCL16. In conclusion, the study underscores LGR5 as a particularly useful prognostic biomarker and illustrates the strength of combining biomarkers detecting different subpopulations of cancer cells and/or cells in the tumor microenvironment for predicting recurrence.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745090 | PMC |
| http://dx.doi.org/10.3390/ijms23010403 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Functional and Biological Characterization of the LGR5Δ5 Splice Variant in HEK293T Cells.
Int J Mol Sci
December 2024
Department of Oral and Maxillofacial Plastic Surgery, Faculty of Medicine, Martin Luther University Halle-Wittenberg, 06120 Halle, Germany.
The regulator of the canonical Wnt pathway, leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5), is expressed in the stem cell compartment of several tissues and overexpressed in different human carcinomas. The isoform of the stem cell marker LGR5, named LGR5Δ5 and first described by our group, is associated with prognosis and metastasis in oral squamous cell carcinoma (OSCC) and soft tissue sarcoma (STS). In a proof-of-principle analysis, the function of LGR5Δ5 was investigated in HEK293T cells, a model cell line of the Wnt pathway, compared to full-length LGR5 (FL) expression.
View Article and Find Full Text PDFStem Cell Markers LGR5, LGR4 and Their Immediate Signalling Partners are Dysregulated in Preeclampsia.
Stem Cell Rev Rep
December 2024
The Department of Obstetrics, Gynaecology and Newborn Health/Mercy Hospital for Women, University of Melbourne, 163 Studley Road, Heidelberg, Victoria, 3084, Australia.
Leucine-rich repeat-containing G protein-coupled receptors 5/4 (LGR5/LGR4) are critical stem cell markers in epithelial tissues including intestine. They agonise wingless-related integration site (WNT) signalling. Until now, LGR5/LGR4 were uncharacterised in placenta, where analogous functions may exist.
View Article and Find Full Text PDFRSPO/LGR signaling regulates proliferation of adult hippocampal neural stem cells.
Stem Cells
October 2024
Institute of Biomedical Sciences (ICB), Faculty of Medicine and Faculty of Life Sciences, Universidad Andres Bello, Santiago, Chile.
In the dentate gyrus of the adult hippocampus, neurogenesis from neural stem cells (NSCs) is regulated by Wnt signals from the local microenvironment. The Wnt/β-catenin pathway is active in NSCs, where it regulates proliferation and fate commitment, and subsequently its activity is strongly attenuated. The mechanisms controlling Wnt activity are poorly understood.
View Article and Find Full Text PDFArticle Synopsis
- Antibody-drug conjugates (ADCs) are a promising targeted cancer treatment, but none have been approved specifically for colorectal cancer (CRC) yet.
- LGR4/5/6 receptors are commonly found in CRC, and while ADCs targeting LGR5 show strong anti-tumor effects, not all CRC cells express LGR5, leading to challenges.
- A new drug conjugate, R462-CPT2, combines a modified RSPO4 protein with a potent drug and has displayed effective anti-tumor activity in CRC models without significant side effects, making it a strong candidate for CRC therapy.
Article Synopsis
- - Mitochondrial dysfunction in inflammatory bowel disease (IBD) leads to increased oxygen levels in the gut, fostering the growth of certain bacteria and disrupting the balance of the microbiome, which can harm metabolism and immunity.
- - A novel compound called AuPhos enhances mitochondrial function in intestinal cells, reduces colitis symptoms, and restores a healthy gut microbiome in mice models, implying its potential benefits for IBD patients.
- - The study utilized various experimental methods, including animal models and human tissue analyses, showing that AuPhos alters microbial composition and improves oxygen use in gut cells, indicating its role in correcting IBD-related metabolic issues.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!